A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2018
Price : $35 *
At a glance
- Drugs Deferasirox (Primary)
- Indications Beta-thalassaemia; Iron overload
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 08 Dec 2015 Interim results (n=26) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 04 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.